Clinical Trials Logo
  1. Home
  2. Leptomeningeal Metastases
  3. NCT04343573

Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors

Leptomeningeal Metastases Clinical Trial

Official title:
A Phase II Randomized Study Assessing the Efficacy of Proton Craniospinal Irradiation (CSI) vs Involved-field Photon Radiation Therapy for Leptomeningeal Metastases From Solid Tumor Malignancies

Clinical Trial Summary

The investigators are doing this study to find out whether proton craniospinal radiation therapy (proton CSI) or partial photon radiation therapy is more effective at preventing leptomeningeal metastasis from worsening. The proton CSI targets the entire space containing the CSF, brain, and spinal fluid. The partial photon radiation therapy treats only areas where the patient is having symptoms, such as the entire brain or part of the spine. The investigators also want to find out if proton CSI improves the symptoms patients may be experiencing because of the leptomeningeal metastasis. In addition, the investigators will compare the side effects of proton CSI and partial photon therapy. Patients undergoing proton beam RT will receive their treatment at the New York Proton Center in New York, NY. As part of the New York Proton Consortium, MSK has contracted for its faculty to treat patients at the New York Proton Center. If it is unfeasible for patients to get treated at NYPC, patients will have the decision to get treated at ProCure in Summerset, NJ.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04343573
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date April 10, 2020
Completion date April 2025
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT01438021 - Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease N/A
Completed NCT02616393 - Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases Phase 2
Completed NCT03101579 - Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer Phase 1
Not yet recruiting NCT06462092 - Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT03719768 - Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Phase 1
Terminated NCT00005812 - Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma Phase 2
Terminated NCT03661424 - BATs in Patients With Breast Cancer and Leptomeningeal Metastases Phase 1
Active, not recruiting NCT05289908 - Intrathecal Pemetrexed for Leptomeningeal Metastasis Phase 1/Phase 2
Recruiting NCT05184816 - A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis Phase 1
Not yet recruiting NCT03613181 - ANG1005 in Leptomeningeal Disease From Breast Cancer Phase 3
Terminated NCT03275402 - 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases Phase 2/Phase 3
Completed NCT01645839 - Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer Phase 3
Completed NCT03520504 - Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases Phase 1
Completed NCT00992602 - Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer Phase 2
Completed NCT00005811 - Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment Phase 2